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SDC 1. Observed WT changes during 1-year treatment among study participants for whom WTs were recorded FSM
SDC 2. BMI percentiles of study participants1 at time of plasma specimen collection, by gender, Federated States of Micronesia and 
Republic of the Marshall Islands, 2009–2011.
SDC 3. Levofloxacin pharmacokinetic parameters for study participants with MDR LTBI on levofloxacin and ethambutol or 
levofloxacin alone, Federated States of Micronesia (FSM), and Republic of the Marshall Islands (RMI), 2009–2011.
SDC 4. Observations versus individual and population predictions
SDC 5. Conditional weighted residuals (CWRES) versus time
SDC 6. Prediction-corrected visual predictive check
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Background—In the Federated States of Micronesia (FSM) and then the Republic of the 
Marshall Islands (RMI), levofloxacin pharmacokinetics (PK) were studied in children receiving 
directly observed once-daily regimens (10 mg/kg, age >5 years; 15–20 mg/kg, age ≤5 years) for 
either multidrug-resistant tuberculosis (MDR TB) disease or latent infection after MDR TB 
exposure, to inform future dosing strategies.
Methods—Blood samples were collected at 0 (RMI only), 1, 2, and 6 hours (50 children, aged 6 
months to 15 years) after oral levofloxacin at >6 weeks of treatment. Clinical characteristics and 
levofloxacin Cmax, elimination half-life (t1/2), and area under the curve from 0 to 24 hours 
(AUC0–24 hours * µg/mL) were correlated to determine optimal dosage and to examine 
associations. Population PK and target attainment were modeled. With results from FSM, dosages 
were increased in RMI toward the target maximal drug concentration (Cmax) for Mycobacterium 
tuberculosis, 8–12 µg/ml.
Results—Cmax correlated linearly with per-weight dosage. Neither Cmax nor t1/2 was associated 
with gender, age, body mass index, concurrent medications, or pre-dose meals. At levofloxacin 
dosage of 15–20 mg/kg, Cmax ≥ 8 µg/ml was observed, and modeling corroborated a high target 
attainment across the ratio of the area under the free-concentration-versus-time curve to minimum 
inhibitory concentration (fAUCss,0–24/MIC) values.
Conclusions—Levofloxacin dosage should be 15–20 mg/kg for Cmax ≥ 8 µg/ml and a high 
target attainment across fAUCss,0–24/MIC values in children ≥2 years of age.
Keywords
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Introduction
Levofloxacin is a broad-spectrum, fluoroquinolone antibacterial agent [1,2] with activity 
against Mycobacterium tuberculosis in vitro and in humans [3]. It is a well-tolerated, 
potentially effective drug for treating latent tuberculosis infection (LTBI) after exposure to 
multidrug-resistant tuberculosis (MDR TB), defined as TB that is resistant to both isoniazid 
and rifampin, the two most potent first-line TB drugs [4].
Definitive TB pharmacokinetic / pharmacodynamic (PK/PD) targets are lacking for 
levofloxacin. In a murine TB model, the ratio of the area under the free-concentration-
versus-time curve to minimum inhibitory concentration (fAUC/MIC) predicted efficacy for 
moxifloxacin, ofloxacin and sparfloxacin [5]. Most adult TB patients who received 1000 mg 
levofloxacin had fAUC/MIC > 125, a typical target for Gram-negative bacilli [3].
Levofloxacin undergoes renal clearance [6]. The PK profile of levofloxacin has not been 
well described following chronic administration in children. One study reported that body 
weight (WT)-normalized clearance in children <5 years was nearly twice as fast as that in 
adults [7]; those authors recommended levofloxacin 10 mg/kg once daily for children ≥5 
years, and 20 mg/kg divided into twice daily doses for children 6 months to <5 years. A 
recent study showed that serum concentrations in children, following oral doses of 
levofloxacin (15 mg/kg), were lower than expected, possibly because of faster elimination 
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than in adults [8]. For adults, levofloxacin doses of 750 to 1000 mg once daily yield the 
target maximal drug concentration (Cmax), 8–12 µg/ml [3,5] and, on the basis of this, the 
same target has been suggested for children.
During outbreaks of MDR TB, first in Chuuk, Federated States of Micronesia (FSM) [9], 
and then in Majuro, the Republic of the Marshall Islands (RMI), 50 children received 
levofloxacin-based regimens for MDR TB disease or LTBI that was presumed to be MDR. 
In FSM, plasma concentrations were measured at the end of a 1-year regimen of 
levofloxacin as monotherapy or in combination with ethambutol (depending on drug 
susceptibility results for index patients) for LTBI or with multiple medications for MDR TB 
disease. These findings were used to adjust the levofloxacin dosage in RMI children who 
were receiving levofloxacin and ethambutol for LTBI after exposure to MDR TB. 
Levofloxacin PK data from both groups of children were analysed to inform future pediatric 
dosing strategies.
Materials and Methods
Ethics and human subjects protections
Ethics approval was obtained from the Institutional Review Board (IRB) at the Centers for 
Disease Control and Prevention (CDC) and from the IRB of the RMI Ministry of Health 
(MOH). The FSM MOH approved the protocol and relied on the CDC IRB. Pediatric assent 
with parental consent was obtained for children at least 7 years old, and only parental 
consent was obtained for younger children.
Study design
Patients, treatment, and specimen collection—In FSM, at the time of testing, 33 
children aged 0·5 to 15 years (median 8 years; 16 girls, 17 boys) were receiving 5–20 
(median 8·7) mg/kg levofloxacin once daily as an oral solution (25mg/ml) [7], either as 
treatment for MDR TB (n=8) or for presumed MDR LTBI (n=25) as household contacts to 
infectious MDR TB patients with tuberculin skin test > 5 mm; all participated in this study. 
Ten of 33 (30%) children were ≤5 years at treatment initiation. The daily dosages at the start 
of treatment were as recommended (10 mg/kg, age >5 years; 15–20 mg/kg, age ≤5 years), 
but WT gain during treatment, without dose recalculation, lessened the per-WT amounts 
when the study was performed. Dosages were not decreased to 10 mg/kg from 15–20 mg/kg 
daily for three children who had their sixth birthday during treatment. The eight with MDR 
TB disease received multiple medications in addition to levofloxacin; of those with LTBI, 8 
(24%) also received ethambutol 11–37 (median 17) mg/kg with the levofloxacin. After 
directly observed therapy (DOT) for 1 year, blood specimens were collected into heparinized 
tubes at 1, 2, and 6 hours after the dose of levofloxacin, 1–3 hours after breakfast at home.
In a separate MDR TB outbreak in RMI, the FSM findings were used to adjust levofloxacin 
dosing for children ≥5 years to 12 mg/kg, and the doses for all children were recalculated 
quarterly for WT changes. Of 17 participating children, age 1–15 years (median 11 years; 8 
girls, 9 boys) being treated for presumed MDR LTBI as household contacts to infectious 
MDR TB patients with tuberculin skin test > 5 mm, 3 (18%) were ≤5 years at treatment 
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initiation. All 17 had been receiving 6 weeks–6 months of a 1-year regimen of levofloxacin 
11–16 (median 12) mg/kg, once daily as an oral solution (25mg/ml) [7]. None had TB 
disease; all the children also received ethambutol 15 mg/kg daily, at the same time that they 
received levofloxacin. After DOT for >6 weeks, blood specimens were collected into 
heparinized tubes at 0, 1, 2, and 6 hours after the dose of levofloxacin, which was given at 
the study site 1–3 hours after a breakfast at home.
Blood specimens at both sites were centrifuged at a speed of 6000 rpm for 5 minutes, and 
the plasma was collected, immediately for storage at −70°C and shipment on dry ice to the 
University of Florida (Gainesville, FL, USA), where levofloxacin concentrations were 
measured by a high-pressure liquid chromatography assay [3]. All children at both sites 
received levofloxacin as an oral solution; the potency was verified for two vials randomly 
picked from stock at each site (verified by the University of Florida laboratory).
Data sources were clinic medical records covering the entire treatment regimens, including 
the periods after blood collection, data gathered specifically for this study during patient 
encounters, and logbooks maintained by clinic and study staff. Data verification was done on 
all observations and variables. All data were imported for statistical analysis into SAS, 
version 9·2 (SAS Institute Inc., Cary, NC, USA).
Pharmacokinetic and statistical analyses
i) Noncompartmental analysis—A noncompartmental PK analysis was performed 
using the software WinNonlin (Pharsight Corporation Version 5·3, St. Louis, MO, USA). 
Estimates were generated for (abbreviation, unit): first-order elimination rate constant 
(Lambda_Z, hours−1), volume of distribution (V/F, L/kg), clearance (CL/F, L/hour/kg), 
elimination half-life (t1/2, hours), maximal drug concentration (Cmax, µg/mL), time at 
maximal drug concentration (Tmax, hours), and area under the time concentration curve from 
0 to 6 hours (AUC0–6, hours * µg/mL), calculated using the linear trapezoidal rule [10]. F 
denotes the levofloxacin’s bioavailability, which is unknown because only oral 
administration was studied.
Demographic and clinical factors including age, gender, body mass index (BMI), active 
disease or LTBI status, pre-dose food intake, complete drug regimen, and PK parameters 
were tested by univariate or linear regression analysis for correlation with levofloxacin Cmax, 
t1/2 and AUC0–6. HIV co-infection was not included in the model as no patients were HIV-
infected.
ii) Population PK analysis—A population PK analysis including data from all children 
was performed using the software nonlinear mixed effects modeling (NONMEM, Version 
7·2, Icon Development Solutions, Ellicott City, Maryland, USA). NONMEM execution, run 
management, bootstrapping and generation of prediction-corrected visual predictive checks 
(pcVPC) were performed using Perl speaks NONMEM (PsN) and Pirana [11, 12, 13]. 
Goodness of fit and pcVPC plots were generated using the R (Version 2·15·2) packages 
lattice and Xpose (Version 4·3·3) [14, 15]. The first-order conditional estimation method 
(FOCE) with interaction was used. Model development was guided using goodness of fit 
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plots, visual predictive checks, plausibility of parameter estimates, as well as objective 
function and shrinkage values.
One- and two-compartment PK models were tested. For a one-compartment model, the 
population PK parameters estimated included the first-order absorption rate constant (KA, 
hours−1), clearance (CL/F, L/h), and volume of distribution (V/F, L). Initially no covariates 
were accounted for in the model, but were later tested for inclusion in an effort to explain (at 
least) part of the inter-individual variability. To account for size-based differences using WT, 
an allometric model with the exponent fixed to 0·75 and 1 was applied for CL/F and V/F, 
respectively, both using a 70 kg standardized WT. Thus, the population parameters CL/F and 
V/F in the case of a 70 kg patient can be related to CL/FGRP and V/FGRP, the group 
estimates where all subjects with the same WT have the same parameter value (Equation 1 
and 2).
(1)
(2)
WTi represents the individual WT of each patient. Inter-individual variability was estimated 
for each PK parameter using an exponential relationship. A random variable, denoted as η, 
was normally distributed with mean zero and variance ω2. Thus, an individual PK parameter 
estimate can be estimated by relating the group population parameter value and accounting 
for inter-individual variability (Equation 3).
(3)
Pij denotes the estimate of parameter j in the ith individual, θGRP,j is the group value for 
parameter j, and ηij denotes the deviation from the group value for parameter j in the ith 
individual. To estimate residual error, a combined additive and proportional residual model 
was applied. In addition to accounting for size-based differences in PK parameters, a 
maturation function accounting for age-dependent changes in drug clearance also was tested 
for inclusion [16].
Additions of covariates to the PK model were tested using generalized additive modeling 
(GAM) implemented in the Xpose R package. Covariates available for all subjects included 
post-natal age, gender, WT, height, and breakfast status. For nested models, a p-value of 0·05 
was used to assess statistical significance. Using the final model, one thousand bootstrap 
runs were performed, and the 2·5th, median, and 97·5th percentiles were calculated based on 
all samples generated.
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Data from all 50 children (33 FSM, 17 RMI) were included in the analysis. With the 
exception of two 0-hour samples, all concentrations were greater than the assay 
quantification limit (0·2 µg/mL). For the two samples, the concentrations were 
approximately half the cutoff limit, and we retained them in the analysis.
iii) Dosing simulations and target attainment analysis—The final population PK 
model was used to perform simulations that can help inform dosing recommendations. 
Briefly, four dosing scenarios were considered: 5, 10, 15 and 20 mg/kg administered daily. 
For each dose, the dataset utilized in the model development phase was used to generate 
simulated PK measurements for an additional 200 replicate datasets (i.e., 50 subjects/
dataset*200 datasets = 10,000 virtual subjects); whereby additional measurements were 
simulated for the 12, 18 and 24 hour time points. The area under the free concentration 
versus time curve from 0 to 24 hours at steady state (fAUCss,0–24) was calculated using the 
trapezoidal rule and an unbound fraction of 0·75 [17]. Box and whisker plots were generated 
in an effort to relate pediatric and adult levofloxacin exposure following multiple dosing. 
Estimates of median adult exposure were obtained from U.S. Food and Drug Administration 
clinical pharmacology review documents (http://www.fda.gov/downloads/Drugs/
DevelopmentApprovalProcess/DevelopmentResources/UCM252889.pdf). Next, a target 
attainment analysis was performed whereby plausible MIC values for M. tuberculosis (0·25, 
0·5, 1, and 2 µg/mL) were related to drug exposure at steady state (fAUCss,0–24/MIC). 
Since a validated target is not available for this population, target attainment was evaluated 
across a range of target values (40, 80, 100, and 125).
Results
Patient characteristics, treatment doses, and noncompartmental pharmacokinetics
The levofloxacin-based treatment regimens lasted 18 months for MDR TB and 12 months 
for MDR LTBI, and all 50 patients completed treatment without side effects necessitating 
interruptions or discontinuation. Twenty-five of 33 (76%) of FSM patients had WT recorded 
after treatment was started; WT increased a median of 4 kg (range −1 to 13) during the year 
as illustrated in Supplemental Digital Content 1 (Figure). Levofloxacin dosages had not been 
adjusted for WT change for any of these participants, and the day of blood collection 
coincided with the final days of treatment for all 33.
Descriptive data on study participants are presented in Tables 1 and Supplemental Digital 
Content 2 (table). In both FSM and RMI, there was representation of children ≤5 years to 17 
years of age (Table 1). In both island groups, gender distribution (males:females) of 
participants was similar (Table 1). The majority (84%) of participants reported food intake 
on the morning of plasma specimen collection (Table 1). Forty-eight had WT and height 
measurements, and BMI was normal for 34 of 48 (71%), with 11 of 48 (23%) being 
overweight or obese and two of 48 (4%) being underweight (Supplemental Digital Content 
2, table).
For the 23 FSM children >5 years at treatment initiation, median Cmax was 6.04 µg/ml 
(range 1·97–10·31) from a median dosage of 8·55 mg/kg (range 5·10–12·73). For 14 RMI 
children >5 years, clinicians increased the dosage to 12 mg/kg and recalculated for WT gain 
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one week prior to blood sample collection; this resulted in median dosages of 11·76 mg/kg 
(range 11·33–13·65) and a median Cmax of 7·69 µg/ml (range 5·54–11·59). For 11 of 13 
children ≤5 years at both sites who received ≥12 mg/kg, Cmax was ≥8·0 µg/ml (Figure 1). 
Cmax correlated linearly with per-WT dosage (R2=0·72), and the per-patient variance from 
the linear relationship was not explained by gender, age, BMI, concomitant medication 
administration, or prior food intake. T1/2 did not correlate with age (R2=0·03) or other 
demographic factors. Cmax was unaffected by ethambutol intake at both sites (Supplemental 
Digital Content 3, table). Levofloxacin concentration-versus-time plots stratified by study 
site are shown in Figure 2. A non-compartmental analysis was performed and the results 
were stratified by age (Table 2). Only three children were <2 years. Findings were largely 
consistent across the age groups, particularly for children ≥2 years.
Population pharmacokinetics and simulation studies
A one compartment PK model described the data well (Table 3). Of the available covariates, 
only WT was included in the final model. A maturation function accounting for age-
dependent changes in clearance did not improve the data fit. Population estimates for KA, 
CL/F, and V/F (the latter two parameters for a 70-kg standardized WT) were 2·69 hours−1, 
11·61 liters/hour, and 88.39 liters, respectively. Inter-individual variability (%CV) was 
estimated as 82·46%, 33·17%, and 24·49% for KA, CL/F, and V/F, respectively. Goodness of 
fit plots and a visual predictive check are shown in Supplemental Digital Content 4, 5, and 6 
(figures)
Utilizing the final population PK model (Figure 3), median free drug exposure, i.e., area 
under the free concentration versus time curve 0–24 hours at steady state (fAUCss,0–24), for 
simulated pediatric data following 10 and 20 mg/kg administered once daily closely 
approximated reported median steady-state adult exposure following 500 and 750 mg 
levofloxacin doses [18]. A dose of 5 mg/kg/day resulted in suboptimal exposure. Using 
simulated pediatric exposure and typical minimal inhibitory concentrations (MIC), 
fAUCss,0–24/MIC was calculated, and target attainment was related for various potential 
target values (Figure 4). In general, a 5 mg/kg dose resulted in poor target attainment 
regardless of the target. With the exception of a fAUCss,0–24/MIC target of 40, for MIC 
values ≥ 0·5 µg/mL, a poor, albeit dose-dependent, target attainment was observed across 
doses. For MIC < 0·5 µg/mL, a 15 mg/kg dose administered once daily achieves a high 
target attainment for a fAUCss,0–24/MIC target of 40. For a MIC 0·5 µg/mL, a 20 mg/kg dose 
administered once daily achieves a high target attainment across fAUCss,0–24/MIC target 
values.
Discussion
In the context of two MDR TB outbreaks, 50 children received levofloxacin-based regimens 
for MDR TB or MDR LTBI, and analyses of PK data derived from plasma specimens 
showed that (1) 15–20 mg/kg dosing daily may be required to achieve a Cmax of ≥ 8 µg/ml in 
children ≥2 years, (2) children aged 2 to 5 years might not need a different dosage or dosage 
schedule, because the half-life of elimination was similar to that of older children, (3) 
additional studies are needed in children <2 years to clarify the developmental PK(/PD) in 
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this age group, and (4) in pediatric patients, WT should be checked every 3 months for dose 
recalculations. Our results differ from two other studies suggesting that children achieve 
lower plasma levofloxacin concentrations compared to adults using the same dosage 
structure [7,8]. The differences may reflect our study population and the drug formulation 
(i.e., oral suspension in our study).
Treatment of 32 adult MDR TB contacts in FSM with 400 mg daily of moxifloxacin 
necessitated obtaining plasma concentrations to confirm adequate dosing (data not shown); 
these efforts revealed similar plasma concentrations of moxifloxacin to those shown in other 
adult patient populations [6], suggesting that the metabolism of fluoroquinolones in 
Micronesians is similar to that in other patients. In this study, the lack of significant gender-
based differences in levofloxacin PK was consistent with reports elsewhere [6]. A limitation 
of the study is that the data included only three children <2 years, and thus were too sparse 
to be definitive for that age group.
Due to their safety and bactericidal activity against M. tuberculosis, fluoroquinolones have 
become a preferred treatment for MDR LTBI in adults [19], despite the absence of clinical 
trials of their use for MDR-TB treatment. In a systematic review of levofloxacin used as 
treatment for LTBI [20], six studies with a total of eight study arms were included, and no 
severe adverse events were reported. The literature on long-term use of fluoroquinolones in 
children is sparse, hampered in part by concern of risk of injury to the musculoskeletal 
system and other serious adverse reactions [21–23]; many children have been treated with 
fluoroquinolones for short durations without arthropathy or bone abnormalities [24, 25]. 
Case reports of children treated with fluoroquinolones for >6 months have found no specific 
toxicity of these agents that is unique to children and no evidence of cartilage effects [24], 
and rates of reversible arthralgia have been similar to those in adults [24, 25]. In the data 
presented here, all of the 50 children received levofloxacin for at least a year without 
interruptions for severe adverse events or discontinuation in FSM [9] and RMI.
Estimates for clearance and volume of distribution obtained for the non-compartmental 
analysis were reasonably close to those previously reported following administration of a 
single 7 mg/kg dose to children ages 0·5 to 16 years, in which a two-fold difference in 
clearance was noted between children <5 years and adults [7]. Differences of this magnitude 
in clearance were not noted between younger and older children in our analyses, potentially 
due to the limited number of children 0·5 to 2 years of age. Typically, 90% of the adult 
glomerular filtration rate is attained by 1 year of age. With a larger sample size in this age 
range, the maturation in renal clearance, and therefore in levofloxacin clearance, might have 
been apparent [26].
Two publications have used PK data in children to make dosage recommendations that 
would match levofloxacin exposures observed in adults following administration of 500 mg 
once daily. In one, children < 5 years cleared levofloxacin nearly twice as fast as adults and, 
as a result, have a total systemic exposure approximately half that of adults; hence, to 
provide similar levofloxacin exposures, children ≥ 5 years would need a daily dose of 10 
mg/kg, while younger children should receive 10 mg/kg every 12 hours [7]. In the other, 
when pharmacometric analyses were used to make recommendations for treatment of post-
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exposure inhalational anthrax in children, a once daily dose of 15 mg/kg resulted in 
levofloxacin exposures comparable to those seen in adults, but Cmax at steady state was 
higher than that reported in adults; as a result, 8 mg/kg taken twice daily was recommended 
[27].
Simulations were performed in an effort to relate pediatric and adult levofloxacin exposure 
at steady-state, with once daily regimens for convenience of directly observed therapy. 
Median simulated exposure following daily 10 and 20 mg/kg dosages matched the exposure 
observed in adults following 500 and 750 mg doses, respectively. A dosage of 15 mg/kg may 
be preferred to match a 500 mg adult dose, as fewer children would have less than the 
median exposure observed in adults. If higher drug exposures are needed, then 20 mg/kg 
should be considered. This sample included few children <2 years, and thus changes in 
clearance with age were unlikely to be captured.
Target attainment analyses were performed using simulated pediatric exposure, with 
multiple targets, as no validated drug exposure target exists for this population. Some have 
suggested that when target attainment rates fall below 90%, the probability of antimicrobial 
drug efficacy is reduced [28]. In our simulations, for the lower levofloxacin dose (5 mg/kg), 
regardless of the target selected, poor target attainment was predicted. For MIC values <0·5 
µg/mL, high target attainment was observed when a fAUCss,0–24/MIC of 40 was sought with 
15 mg/kg dosage. The wild-type in vitro MIC of levofloxacin is 0·125–0·5 µg/mL, 
suggesting that the cutoff for levofloxacin susceptibility could be MIC ≤0·5 µg/mL. These 
MIC data have correlated with BACTEC 960 MGIT and BACTEC 460 results [29]. Our data 
support once daily levofloxacin 15 mg/kg for children. However, for higher MIC values 
(≥0·5 µg/mL), high target attainment was observed for 20 mg/kg and a fAUCss,0–24/MIC 
greater than 40. For MIC 0·5 µg/mL, once daily 20 mg/kg would be preferred across target 
values. These analyses underscore the need for investigating appropriate targets for PK/PD 
indices that can be used to optimize levofloxacin dosing.
In these outbreaks, lack of TB disease among all 42 levofloxacin-treated pediatric patients 
with LTBI who were followed for at least 2 years after treatment completion, and the 
development of active TB disease in 3 of 15 untreated children with LTBI [9], suggest that 
these empirical levofloxacin regimens may prevent progression to MDR TB. Experience 
with more patients, with long-term follow-up, will be essential to prove effectiveness of 
MDR LTBI regimens, but based on the experience in FSM [9] and RMI, levofloxacin-based 
MDR LTBI treatment is adequately tolerated, potentially effective, and feasible even in a 
resource-poor setting.
To achieve a target Cmax ≥ 8 µg/ml in children, revision of the current dosage 
recommendations for levofloxacin should be considered; 15–20 mg/kg of levofloxacin once 
per day appears to be indicated, at least for children ≥2 years of age. Based on modeling, for 
MIC < 0·5 µg/mL, high target attainment was achieved with 15 mg/kg daily dosing. For 
MIC ≥ 0·5 µg/mL, 20 mg/kg daily should be considered. Further clinical research is needed 
to evaluate appropriate targets for PK/PD indices that can be used to optimize drug dosing 
and to refine dosage recommendations for children <2 years.
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FIGURE 1. 
Maximal levofloxacin concentration (Cmax, µg/mL) as a function of drug dosage in children 
treated with levofloxacin for ≥ 6 weeks, Federated States of Micronesia (FSM; n=33) and 
Republic of the Marshall Islands (RMI; n=17). Regression lines from least-squares (see 
Supplemental Digital Content).
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FIGURE 2. 
Levofloxacin concentration over time, by study site, Federated States of Micronesia (FSM; 
n=33) and Republic of the Marshall Islands (RMI; n=17).
Mase et al. Page 13
Pediatr Infect Dis J. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIGURE 3. 
Area under the concentration versus time curve for the unbound drug obtained at steady state 
(fAUCss,0–24) following for various daily doses of levofloxacin (5, 10, 15, and 20 mg/kg). 
The lower, middle, and upper solid lines represent the median fAUCss,0–24 reported for 
adults following 500 mg once daily dosing, 750 mg once daily, and 1,000 mg once daily, 
respectively. An estimate for the 1000 mg daily dose was obtained from Peloquin et al. (1), 
while the estimates for 500 mg and 750 mg daily doses were obtained from clinical review 
documents [3 and 18]. A fraction unbound of 0.75 was assumed to calculate unbound 
exposure.
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FIGURE 4. 
Target attainment analysis performed by applying the developed PK model to simulate 
10,000 virtual children (50 children/dataset * 200 simulations) and calculate likelihood of 
attaining various fAUC/MIC targets (40, 80, 100 or 125) following steady state dosing of 
levofloxacin (5, 10, 15 or 20 mg/kg).
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Table 1
Characteristics of study participants at time of blood specimen collection, Federated States of Micronesia 
(FSM), and Republic of the Marshall Islands (RMI), 2009–2011.
FSM (N=33) RMI (N=17) Total (N=50)
Characteristic
Age (years), mean±SD 8·5 ± 3·7 11·0 ± 4·8 9·3 ± 4·2
  ≤ 5 years, n (%) 10 (30) 3 (18) 13 (26)
  5 – <11 years, n (%) 12 (36) 4 (24) 16 (32)
  11 – 17 years, n (%) 11 (34) 10 (59) 21 (42)
Weight (kg), mean±SD 26·2 ± 9·2 34·9 ± 17·2 29·2 ± 13·1
Height (m), mean±SD 1·18 ± 0·20 1·31 ± 0·28 1·23 ± 0·24
Gender, n (%)
    Male 17 (52) 9 (53) 26 (52)
    Female 16 (49) 8 (47) 24 (48)
Food intake 1–3 hours before, n (%)
    Yes 29 (91) 12 (71) 41 (84)
    No 3 (9) 5 (29) 8 (16)
Participant status, n (%)
    Case 8 (24) 0 (0) 8 (16)
    Contact (all) 25 (76) 17 (100) 42 (84)
Drug regimen, n (%)
    Levofloxacin 17 (52) 0 (0) 17 (35)
Levofloxacin/Ethambutol 8 (24) 17 (100) 32 (65)
      MDR regimen 8 (24) 0 (0) 8 (24)
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TABLE 3
Population parameter estimates from the final pharmacokinetic model and a bootstrap analysis (n=1,000).
Parameter
Estimate
RSE (%) Bootstrap (n=1,000)
Median (95% CI)a
Structural Model
KA (h−1) 2·69 22 2·62 (1·89–5·31)
CL/F (L/h)b 11·61 5 11·61 (10·34–12·82)
V/F (L)b 88·39 4 87·77 (80·8–95·26)
Inter-individual Variability (%CV)
ω (KA) 82·46 42 79·93 (46·9–119·5)
ω (CL/F) 33·17 28 32·25 (22·36–41·47)
ω (V/F) 24·49 50 23·23 (10–33·76)
Residual Error
Proportional (%) 12 38 11·83 (4·69–16·73)
Additive (µg/mL) 0·29 56 0·29 (0·01–0·53)
RSE, Relative standard error; CI, Confidence interval
a
Bootstrap: median (2·5–97·5 percentile)
bCL/F and V/F were scaled using a 70 kg standardized weight.
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